Organon & Co (OGN) concluded trading on Wednesday at a closing price of $16.00, with 3.89 million shares of worth about $62.3 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.68% during that period and on January 08, 2025 the price saw a gain of about 1.78%. Currently the company’s common shares owned by public are about 257.54M shares, out of which, 256.98M shares are available for trading.
Stock saw a price change of 7.24% in past 5 days and over the past one month there was a price change of 5.82%. Year-to-date (YTD), OGN shares are showing a performance of 7.24% which decreased to -1.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.87 but also hit the highest price of $23.10 during that period. The average intraday trading volume for Organon & Co shares is 3.28 million. The stock is currently trading 6.34% above its 20-day simple moving average (SMA20), while that difference is up 2.47% for SMA50 and it goes to -15.17% lower than SMA200.
Organon & Co (NYSE: OGN) currently have 257.54M outstanding shares and institutions hold larger chunk of about 81.18% of that.
The stock has a current market capitalization of $4.12B and its 3Y-monthly beta is at 0.71. PE ratio of stock for trailing 12 months is 3.17, while it has posted earnings per share of $5.04 in the same period. Its PEG reads 0.62 and has Quick Ratio of 1.21 while making debt-to-equity ratio of 17.75. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OGN, volatility over the week remained 3.91% while standing at 3.74% over the month.
Stock’s fiscal year EPS is expected to rise by 0.06% while it is estimated to increase by 0.06% in next year. EPS is likely to grow at an annualized rate of 5.13% for next 5-years, compared to annual growth of -14.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on September 06, 2024 offering an Underweight rating for the stock and assigned a target price range of between $18 and $20 to it. Coverage by Goldman stated Organon & Co (OGN) stock as a Neutral in their note to investors on November 03, 2023, suggesting a price target of $16 for the stock. On September 21, 2023, Barclays Initiated their recommendations, while on March 16, 2023, Raymond James Initiated their ratings for the stock with a price target of $33. Stock get an Underperform rating from BofA Securities on October 14, 2022.
